Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2891-1-001PCT/US 10/524359
	SERIAL NO.	Unassigned
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Benoit Chabot et al.
	FILING DATE	Herewith
	GROUP	Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/DS/	CA	Skordis, L, etal, Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts, 2003, PNAS, Vol 100, No. 7, Pgs. 4114-4119.
	CB	Cartegni, L, etal, Correction of disease-associated exon skipping by synthetic exon-specific activators, 2003, Nat. Struct. Bio., Vol 10, No.2, Pgs. 120-125.
	CC	Shirohzu, H., etal, Repression of Aberrant Splicing in Human β-Globin Pre-mRNA With HbE Mutation by Antisense Oligoribonucleotide or Splicing Factor SF2/ASF, 2000, Intl Jour. of Hemat., Pgs. 28-33.
	CD	Taylor, J, etal, Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides,1999, Abstract-Nature Biotech. -XP-002262732-Pgs.1097-1100.
	CE	Lacerra G, etal, Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients, 2000, Abstract-PNAS-XP00226733-Pgs. 9591-9596.
	CF	Chabot,B.,etal, An Intron Element Modulating 5' Splice Site Selection in the hnRNP A1 Pre-mRNA Interacts with hnRNP A1, 1997, Molecular & Cell. Bio-Amer Soc. For Micro., Pgs. 1776-1786.
/DS/	CG	Burd,C,etal,RNA binding specificity of hnRNP A1:significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing, 1994, EMBO Jour., Pgs. 1197-1204.

EXAMINER: /Dana Shin/	DATE CONSIDERED: 01/25/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2891-1-001PCT/US
	SERIAL NO.	10/524,359
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary) **SUPPLEMENTAL**	APPLICANT	Benoit Chabot et al.
	FILING DATE	February 14, 2005
	GROUP	Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/DS/	CE	Lacerra G, etal, Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients, 2000, **FULL ARTICLE**, Pgs. 9591-9596. **(Note: On IDS filed 2-14-05 we included an ABSTRACT ONLY for this article)**
	CH	VILLEMAIRE et al., Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides, J. Biol. Chem., Vol, 278, No. 5050031-50039 (2003).
	CI	NASIM et al., High-affinity hnRNP AI binding sites and duplex-forming inverted repeats have similar effects on 5' splice site selection in support of a common looping out and repression mechanism, RNA, V o l . 8:1078-I 079 (2002)
	CJ	GOYENVALLE et al., Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, Vol. 306:1796-I 799 (2004).
	CK	DOMINSKY et al., Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides, Proc. Natl. Acad. Sci. USA, Vol. 90:8673-8677 (1993).
	CL	SIERAKOWSKA et al., Repair of thalassemic human R-globin mRNA in mammalian cells by antisense oligonucleotides, Proc. Natl. Acad. Sci. USA, Vol. 93:12840-12844 (1996).
/DS/	CM	FRIEDMAN et al., Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides, J. Biol. Chem., Vol. 274, No. 51:36193-36199 (1999).

EXAMINER: /Dana Shin/	DATE CONSIDERED: 01/25/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2891-1-001PCT/US
	SERIAL NO.	10/524,359
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Benoit Chabot et al.
	FILING DATE	February 14, 2005
	GROUP	Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/DS/	CN	SUTER et al., Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations, Hum. Mol. Gen., Vol. 8, No.13:2415-2423 (1999).
	CO	SIERAKOWSKA et al., Sensitivity of splice sites to antisense oligonucleotides in vivo, RNA, Vol. 5:369-377 (1999).
	CP	KARRAS et al., Peptide nucleic acids are potent modulators of endogenous Pre-mRNA splicing of the murine interleukind receptor-α chain, Biochem., Vol. 40:7853-7859 (2001).
	CQ	SAZANI et al., Nuclear antisense effects of neutral, anionic and cationic and cationic oligonucleotide analogs, Nuci. Acid Res., Vol. 29, No. 19:3965-3974 (2001).
	CR	DOMINSKY et al., identification and characterization by antisense oligonucieotides of exon and intron CM sequences required for splicing, Mol. and Cell. Biol., Vol. 14, No. 11:7445-7454 (1994).
	CS	MERCATANTE et al., Modification of alternative splicing pathways as a potential approach to chemotherapy, Pharmac. and Therap., Vol. 85237-243 (2000).
/DS/	CT	WILTON et al., Specific removal of the non-sense mutation from the mdx dystrophin mRNA using antisense oiigonucieotides, Neuromusc. Dis., Vol. 9:330-338 (1999).

EXAMINER: /Dana Shin/	DATE CONSIDERED: 01/25/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2891-1-001PCT/US
	SERIAL NO.	10/524,359
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Benoit Chabot et al.
	FILING DATE	February 14, 2005
	GROUP	Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/DS/	CU	GORMAN et al., Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs, Proc. Nati., Acad. Sci. USA, Vol. 95:4929-4934 (1998).
	CV	SUTER et al., Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations, Hum. Mol. Gen., Vol. 8, No. 13:2415-2423 (1999).
	CW	SAZANI et al., Systemically delivered antisense oligomers upregulate gene expression in mouse tissues, Nature Biotech., Vol. 20: 1228-I 233 (2002).
	CX	SAZANI et al., Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing, J. Clin. Invest., Vol. 112, No. 4:481-486 (2003).
	CY	MERCATANTE et al., Modification of alternative splicing of bcl-x pre-mRNA in prostate and breast cancer cells, J. Biol. Chem., Vol. 276, No. 19:16411-16417 (2001).
/DS/	CZ	MERCATANTE et al., Cellular response to an antisense-mediated shift of bcl-x pre-mRNA splicing and antineoplastic agents, J. Biol. Chem., Vol. 277, No. 51:49374-49382 (2002).

EXAMINER: /Dana Shin/	DATE CONSIDERED: 01/25/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.